Fortunately, this situation has started to change very recently, owing to the introduction into the market of novel drugs with potent activity against some MDR-GNB such as carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) ( 5, 6). This has forced clinicians to consider treatment approaches based on combinations of drugs with impaired activity, and/or to rediscover old drugs with suboptimal pharmacokinetics and toxicity issues, all in the absence of high-level evidence to firmly guide bedside decisions ( 3, 4). Indeed, although the development of resistance has accompanied antimicrobial therapy since its dawn, only in recent years GNB have started, in non-negligible numbers, to manifest concomitant resistance to all commonly used classes of antimicrobials. In the last 15 years, intensivists, and infectious diseases consultants have started to face novel peculiar challenges in the treatment of severe infections in critically ill patients in intensive care units (ICU), due to the selection and diffusion of multidrug-resistant Gram-negative bacteria (MDR-GNB) ( 1, 2). Treatment of severe MDR-GNB infections in critically ill patients in the near future will require an expert and complex clinical reasoning, of course taking into account the peculiar characteristics of the target population, but also the need for adequate empirical coverage and the more and more specific enzyme-level activity of novel antimicrobials with respect to the different resistance mechanisms of MDR-GNB. Despite important progresses, pharmacokinetic/pharmacodynamic optimization of dosages and treatment duration in critically ill patients has still some areas of uncertainty requiring further study, that should take into account also resistance selection as a major endpoint. However, their optimal use should be guaranteed in the long term, for delaying as much as possible the emergence and diffusion of resistance to novel agents. In the past few years, new treatment options, such as ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, plazomicin, and eravacycline have become available, and others will become soon, which have provided some much-awaited resources for effectively counteracting severe infections due to these organisms. Carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii are being reported with increasing frequencies worldwide, although with important variability across regions, hospitals and even single wards. Rapid diagnostics and efficient laboratory workflows are also of paramount importance both for anticipating diagnosis and for rapidly narrowing the antimicrobial spectrum, with de-escalation purposes and in line with antimicrobial stewardship principles. In this light, readily available patient's medical history and updated information about the local microbiological epidemiology remain critical for defining the baseline risk of MDR-GNB infections and firmly guiding empirical treatment choices, with the aim of avoiding both undertreatment and overtreatment. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible unfavorable consequences. The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. 2Department of Health Sciences, University of Genoa, Genoa, Italy.1Clinica Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy. Matteo Bassetti 1 * Maddalena Peghin 1 Antonio Vena 1 Daniele Roberto Giacobbe 2
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |